Constellation Pharmaceuticals Inc

Constellation Pharmaceuticals — Investor Presentation (December 2018)

37 slides from Constellation Pharmaceuticals's investor presentation, Dec 10, 2018

  1. Slide 1: Corporate Overview December 2018

    Developing Treatments Targeting Epigenetic Mechanisms in Tumor and Immune Cells for Cancer Patients Corporate Overview December 2018 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development status of the Company’s product candidates, the anticipated benefits of

  3. Slide 3: Constellation Highlights

    Multiple Lead Clinical Programs CPI-1205 (EZH2) and CPI-0610 (BET) Encouraging Preliminary Clinical Data Prostate cancer, solid tumors, and myelofibrosis Near-Term Milestones Proof-of-concept determination for each lead program expected in mid-2019 Expanding the EZH2 Opportunity Second-generation EZ

  4. Slide 4: Focused on Three Distinct Classes That Chemically Modify Chromatin

    Instructions for Genetic Code Tumor Cells MDSC NK Cell T Cell Focused on Three Distinct Classes That Chemically Modify Chromatin Tumor Microenvironment Target Transcriptional Networks That Result in Cell Death Re-program Immune Cells to Overcome Resistance to Cancer Immunotherapies Transcriptional C

  5. Slide 5: Multiple Near-Term Opportunities for Success

    Multiple Near-Term Opportunities for Success Product Candidates Indications Preclinical Phase 1 Phase 2 Phase 3 Next Milestone EZH2 Franchise CPI-1205 mCRPC Proof of Concept Mid 2019 CPI-1205 Solid Tumors Safety and RP2D for Pembro Arm Early 2019* CPI-0209 (2nd Gen) Solid Tumors / Heme Malignancies

  6. Slide 6: CPI-1205 and CPI-0209 EZH2 Franchise

    CPI-1205 and CPI-0209 EZH2 Franchise

  7. Slide 7: EZH2 Writer Activity Suppresses Gene Transcription

    EZH2 “Writer” Activity Suppresses Gene Transcription EZH2 Inhibition Offers Broad Therapeutic Potential Polycomb Repressive Complex 2 (PRC2)… … Methylates Histone H3 at Lysine 27 (K27) EZH2 SUPPRESSED TRANSCRIPTION Acquired Drug Resistance: EZH2 mediates gene silencing that diminishes response to ex

  8. Slide 8: Model for EZH2 Role in Prostate Cancer

    *Signature of H3K27me3-occupied EZH2 target genes repressed in metastatic relative to clinically localized prostate cancer and benign prostate tissue Model for EZH2 Role in Prostate Cancer EZH2 Gene Signature* Predicts Outcomes in Prostate Cancer Yu et al., Cancer Research 2007 Pro-tumor Signaling E

  9. Slide 9: Evidence of EZH2 Synergy with Androgen Receptor Signaling

    Evidence of EZH2 Synergy with Androgen Receptor Signaling (ARS) CPI-1205 Enhances the Gene Signature of Enzalutamide in Prostate Cancer Cells CPI-1205 is Active as Monotherapy and Synergistic with Enzalutamide in Killing Prostate Cancer Cells Enzalu- tamide CPI- 1205 Combo Theoretical concentration

  10. Slide 10: 2L mCRPC Patients Suffer Poor and Short Responses

    2L mCRPC Patients Suffer Poor and Short Responses to Abiraterone and Enzalutamide *ASCO 2018 Poster Khalaf, et al (Kim Chi Lab) PSA 80 > PSA30 = 6% > PSA50 = 4% > PSA80 = 0% PSA PFS = 1.3 months TTP = 1.6 months > PSA30 = 43% > PSA50 = 31% > PSA80 = 10% PSA PFS = 2.7 months TTP = 2.7 months Goal: Tr

  11. Slide 11: Current Treatment Paradigm in mCRPC

    Current Treatment Paradigm in mCRPC mCRPC 1st Line Abiraterone or Enzalutamide 2nd Line Enzalutamide or Abiraterone (Poor Activity) 3rd Line Chemotherapy or Palliative Care EZH2 inhibition may enhance the activity of ARS inhibitors and reduce need for chemotherapy Pre-Metastatic Prostate Cancer May

  12. Slide 12: ProSTAR Trial Design

    Phase 2 Expanded to Include Enzalutamide and Abiraterone ProSTAR Trial Design Testing Biomarkers for Patient Enrichment Enzalutamide + CPI-1205 (Progressed on Abiraterone) n = ~ 35 Enzalutamide Alone (Progressed on Abiraterone) n = ~ 35 vs. Primary endpoints: MTD, RP2D Primary endpoint: Response rat

  13. Slide 13: Resolution of Bone Metastases

    *Continued on CPI-1205 monotherapy after cycle 1 Resolution of Bone Metastases Baseline Cycle 4 Day 1 CPI-1205 + Enzalutamide*

  14. Slide 14: Objective Response by CT Scan

    Objective Response by CT Scan February 2018 Baseline: December 2017 CPI-1205 + Enzalutamide

  15. Slide 15: ProSTAR Trial: Treatment Duration

    Data cutoff May 25, 2018 *Continued on CPI-1205 monotherapy after cycle 1 Discontinued treatment ProSTAR Trial: Treatment Duration 2 of 6 evaluable patients achieved PSA reduction of >80% 2 of 4 evaluable patients with CTCs achieved CTC reduction of > 30% 2 of 2 evaluable patients had resolution of

  16. Slide 16: Phase 1b Endpoints Achieved; Phase 2 Initiated

    Phase 1b Endpoints achieved Well-tolerated Robust PK/PD profile Clinical activity across all three parameters (objective responses, PSA reductions, CTC reductions) In combination with either abiraterone or enzalutamide Phase 2 Expansion Portion of ProSTAR Initiated Expanding original plan in order t

  17. Slide 17: Significant PSA Reduction in Compassionate-Use Patient

    Significant PSA Reduction in Heavily Pre-Treated and Refractory Patient Experience with a Compassionate-Use Patient 3,000 2,500 2,000 1,500 1,000 500 12 agents prior to CPI-1205, including second-generation androgen inhibitors, chemotherapy, PARP inhibitors, tyrosine kinase inhibitors, checkpoint in

  18. Slide 18: CPI-0209: Second-Generation EZH2 Inhibitor

    Tazemetostat CPI-0209 Once-Daily Treatment Resulted in Rapid, Complete, and Durable Tumor Regression CPI-0209: Second-Generation EZH2 Inhibitor CPI-0209 May Provide More Comprehensive EZH2 Coverage, Expanding Addressable Populations Lymphoma Xenograft Mouse Model Vehicle Tazemetostat, 160 mg/kg oral

  19. Slide 19: CPI-0610 BET Inhibitor

    CPI-0610 BET Inhibitor

  20. Slide 20: CPI-0610 Background

    Treated 138 patients in Phase 1 trials of hematologic malignancies Multiple objective responses observed at a range of doses below the maximum tolerated dose Demonstrated favorable PK/PD profile Activity seen in the context of NF-κB-driven diseases ABC-DLBCL (Phase 1) 7 patients at relevant doses: 1

  21. Slide 21: Control of Key Immune, Fibrotic, and Oncogenic Pathways

    Control of Key Immune, Fibrotic, and Oncogenic Pathways Leads to Opportunity in Myelofibrosis (MF) BET Family of Proteins … Enhancer TSS BRD4 Transcription Factor … Fibrosis TGF-β target genes Immune Signaling NF-κB target genes Cancer Genetics MYC, BCL2

  22. Slide 22: BET Inhibition May Block Proliferation of Inflammatory Bone Marrow Cells

    BET Inhibition May Block Proliferation of Inflammatory Bone Marrow Cells and Synergize with JAK Inhibition BET Role in Myelofibrosis BET Signaling Megakaryocyte Differentiation/Proliferation Pro-Inflammatory Cytokines (e.g., IL-8) JAK/STAT Signaling STAT STAT Cytoplasm Nucleus NF-kB Target Genes BET

  23. Slide 23: Data Rationale for Targeting BET Inhibition in Myelofibrosis

    Constellation Pharmaceuticals Data Rationale for Targeting BET Inhibition in Myelofibrosis CPI-0610 vs DMSO 25 nM 100 nM 400 nM Vehicle 1–2+ JQ1 (BETi) 1+ Ruxolitinib 1+ Combo 0 Inhibition of Megakaryocyte Differentiation in vitro BET Inhibitor + Ruxolitinib Led to Synergistic Reduction in Spleen Vo

  24. Slide 24: Myelofibrosis (MF) Background

    Myeloproliferative neoplasm characterized by scarring (fibrosis) of the bone marrow caused by impaired hematopoiesis 17,000–20,000 diagnosed patients in US* Three main features: Symptoms of organomegaly (spleen and liver) Symptoms of systemic inflammation Anemia and thrombocytopenia Only approved th

  25. Slide 25: Underserved MF Patient Population

    Standard of care and the only approved drug treatment is ruxolitinib (Jakafi) Significant improvement in splenomegaly and symptoms, but limited evidence of disease-modifying effect 30–40% of patients respond adequately in clinical trials* Thrombocytopenia and/or anemia may lead to patients receiving

  26. Slide 26: Need for New Disease-Modifying Treatments in MF

    Inadequate response in 1L disease No approved therapy in 2L disease Patients burdened by increased reliance on transfusions Need for new disease-modifying therapies that increase response rate and improve hematopoietic function Need for New Disease-Modifying Treatments in MF *Source: Mesa, R., et al

  27. Slide 27: Rationale for MANIFEST Design

    First-line arm in combination with ruxolitinib aims to address inadequate response to ruxolitinib alone in spleen volume reduction, patient-reported symptom improvement, and other factors, including lack of disease-modifying effects of ruxolitinib Second-line arm aims to provide a treatment option,

  28. Slide 28: MANIFEST: Expanded Phase 2 Trial in MF

    * Cohort 3 will enroll anemic patients, pivotal trial plans would include all comers Robust Development Plan to Expand the CPI-0610 Opportunity MANIFEST: Expanded Phase 2 Trial in MF Cohort 1A: 2L Transfusion Dependent (TD) n = ~ 16 Cohort 1B: 2L Non-TD n = ~ 25 Cohort 2A: 2L Transfusion Dependent n

  29. Slide 29: MANIFEST: First Four Patients Treated

    Best Spleen Response Reduced spleen size Symptom improvement One patient with thrombocytosis and one patient transfusion-dependent at baseline—both resolved Spleen Size Reduced in All Patients as Measured by MRI MANIFEST: First Four Patients Treated Data cutoff May 25, 2018 Ongoing > 10 months Ongoi

  30. Slide 30: Improved Hematopoiesis on CPI-0610

    Data cutoff May 25, 2018 Patient Achieved Transfusion Independence and Improved Platelet Count Improved Hematopoiesis on CPI-0610 Patient treated with CPI-0610 + ruxolitinib combination therapy Transfusions No Transfusions for >24 Weeks 4 wks 4 wks 4 wks 6 wks

  31. Slide 31: Hemoglobin Levels Increased in First Four Patients Treated

    Data cutoff May 25, 2018 Hemoglobin Levels Increased in First Four Patients Treated Improved Hematopoiesis on CPI-0610

  32. Slide 32: CPI-0610 Summary

    CPI-0610 has demonstrated clinical activity in early clinical trials with NF-κB-driven cancers, including myelofibrosis, suggesting CPI-0610 may be differentiated among BET inhibitors Preliminary clinical data in 2L myelofibrosis show improvements in spleen volume, symptom scores, hematopoiesis, and

  33. Slide 33: Discovery Platform Fueling the Pipeline

    Discovery Platform Fueling the Pipeline Innate Adaptive Normalize aberrant gene expression within cancer cells Increase tumor immunogenicity Re-program immune cells to overcome resistance to cancer immunotherapies Tumor Cells Immune Cells Discovery Programs Targeting Epigenetic Regulators on the Tum

  34. Slide 34: Financial Strength

    Financial Strength

  35. Slide 35: Potential Value Creation Catalysts

    Potential Value Creation Catalysts 2019 2018 Early 2018 Complete crossover financing Expand enrollment in ProSTAR Initiate ORIOn-E Select 2nd generation EZH2 inhibitor candidate (CPI-0209) Late 2018 Additional active sites in US, Canada / EU for CPI-0610 in myelofibrosis Initiate Phase 2 portion of

  36. Slide 36: Strong Cash Position

    Post-IPO cash expected to fund operations into 2020, including: Ongoing clinical trials to determine proof of concept for CPI-1205 and CPI-0610 Continued advancement of CPI-0209 Ongoing support for robust discovery/preclinical Oversubscribed crossover financing round in April raised $100 million fro

  37. Slide 37: Management Team

    Management Team Jigar Raythatha President and CEO Emma Reeve Chief Financial Officer Adrian Senderowicz, M.D. Chief Medical Officer Brad Prosek SVP, Corporate Development Robert Sims, PhD SVP, Research Patrick Trojer, PhD Chief Scientific Officer Karen Valentine Chief Legal Officer, General Counsel

Constellation Pharmaceuticals — Investor Presentation (December 2018) on 6ix